Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $10.48 and traded as high as $11.54. Eliem Therapeutics shares last traded at $11.01, with a volume of 1,783,991 shares.
Eliem Therapeutics Stock Up 7.0%
The company has a market cap of $327.57 million, a P/E ratio of -20.77 and a beta of -0.39. The company has a fifty day moving average of $11.84 and a 200 day moving average of $10.48.
Eliem Therapeutics Company Profile
Eliem Therapeutics, Inc. is a biopharmaceutical company that historically focused on developing therapies for disorders associated with abnormal neuronal excitability, including neuropathic pain, epilepsy, depression, and anxiety. The company’s research programs were designed to address conditions affecting the central and peripheral nervous systems. Eliem’s development pipeline included ETX-810, an oral prodrug of pregabalin intended to improve the delivery and therapeutic profile of an established treatment for neuropathic pain, and ETX-155, a GABA-A receptor positive allosteric modulator investigated for potential use in neurological and psychiatric disorders.
Recommended Stories
- Five stocks we like better than Eliem Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
